Cognition
CGTX
Cognition (CGTX) news
Recent news
Cognition Thera: registrational program seen starting mid-2027
AInvest Wire · Jun 24, 2026Cognition Therapeutics - registrational program for zervimidine in DLB psychosis to begin mid-2027
Cognition Therapeutics, Inc. (NASDAQ: CGTX) has announced plans to initiate a registrational program for zervimesine (CT1812) in the treatment of psychosis associated with dementia with Lewy bodies (DLB) by mid-2027. This decision follows the presentation of Phase 2 clinical data at the AD/PD™ 2026…
AInvest Wire · Jun 24, 2026Cognition Therapeutics - FDA agrees DLB psychosis could be approvable outcome for zervimidine
AInvest Wire · Jun 24, 2026Cognition Therapeutics reached FDA alignment on CT1812 trial aspects
AInvest Wire · Jun 24, 2026KD Ventures AB - UmeCrine Cognition completes SEK 19.6 mln share issue, part of SEK 64 mln total
AInvest Wire · Jun 8, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.